Dexanabinol

Dexanabinol is a synthetic cannabinoid derivative and the "unnatural" enantiomer of the potent cannabinoid agonist HU‑210. Unlike other cannabinoids, dexanabinol does not act as a cannabinoid receptor agonist but functions primarily as an N-Methyl-D-aspartate (NMDA) receptor antagonist, providing neuroprotective effects by protecting neuronal cells against NMDA and glutamate neurotoxicity. It also acts as an antioxidant, scavenging peroxy radicals and protecting neurons from reactive oxygen species damage. Dexanabinol inhibits nuclear factor kappa B subunit 1 (NF‑κB) signaling by blocking phosphorylation and degradation of IκB, reducing NF‑κB transcriptional activity and downregulating pro-inflammatory cytokines such as TNFα and IL‑6. It has been investigated for use in traumatic brain injury, stroke, cancer (notably brain cancer), and other neurologic disorders. The drug was developed at Hebrew University from Δ8‑THC derivatives and is currently under development by e-Therapeutics[1][2][3][4][5][6][7].

Other names

Sinnabidiol(+)-HU-210